Table 2.
Patient demographics, disease characteristics, and surgical complications by study.
| Study | Patient characteristics | Disease characteristics and treatment | Complications | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Average age | SD | Average BMI (kg/m2) | SD | Breast cancer type | Chemotherapy | Radiation | Reconstruction | Neurotization of NAC | NAC necrosis | Dehiscence | Unplanned reoperation | |
| Benediktsson et al. | 54 | 40–80 (range)∗ | Not provided | Not provided | Not provided | 19 (24%) | 17 (21%) | Nonautologous = 80 (100%) | 0 (0%) | Not provided | Not provided | Not provided |
|
| ||||||||||||
| Chirappapha et al. | 43 | 30–60 (range)∗ | 23.1 | 16.3–43.8 (range)∗ | Invasive carcinoma = 33 (77%) DCIS = 10 (23%) Benign phyllodes tumor = 3 (6%) Benign condition = 8 (15%) |
Not provided | Not provided | Both autologous and nonautologous (numbers not specified) | 0 (0%) | 11 (20%) | Not provided | 3 (5.5%) |
|
| ||||||||||||
| Djohan et al. | 46.5 | 9.42 | 24 | 4.79 | Prophylactic = 12 (15.4%) DCIS (29, 37.2%) LCIS (3, 3.8%) Infiltrating (34, 43.5%) |
Not provided | Not provided | Nonautologous, n = 84 (72.4%) Autologous, n = 32 (27.6%) |
0 (0%) | 2 (2.6%) | Not provided | 31 (39.7%) |
|
| ||||||||||||
| Djohan et al. | 38.12 | 7.5 | 23.66 (4.19) | 4.19 | Not provided | 4 (26.8%) | 0 (0%) | Nonautologous, n = 15 (100%) | 15 (100%) | 2 (13.4%) | 1 (6.7%) | Not provided |
|
| ||||||||||||
| Eichler et al. | 52.9 | 9.3 | Not provided | Not provided | DCIS (14, 9.8%) IDC (104, 72.8%) ILC (18, 12.6%) Others (6, 4.2%) |
94 (65.8%) | Not provided | Not provided | 0 (0%) | Not provided | Not provided | Not provided |
|
| ||||||||||||
| Franceschini et al. | 45.3 | 27–73 (range)∗ | 24.4 | 17.5–29.4 (range)∗ | Not provided | 73 (41.2%) | 45 (25.4%) | Nonautologous = 177 (100%) | 0 (0%) | 1 (1.2%) | Not provided | Not provided |
|
| ||||||||||||
| Gahm et al. | 39 (median)∗∗ | 26–58 (range)∗ | Not provided | Not provided | Prophylactic = 46 (100%) | 0 | Not provided | Nonautologous = 46 (100%) | 0 (0%) | Not provided | Not provided | Not provided |
|
| ||||||||||||
| Glaumann et al. | Not provided | Not provided | Not provided | Not provided | Not provided | Not provided | Not provided | Autologous = 7, 9.7% Nonautologous = 62, 86.1% |
0 (0%) | 4 (3.4%) | Not provided | 41 (35.0%) |
|
| ||||||||||||
| Khan et al. | 51 (median)∗∗ | 30–72 (range)∗ | Not provided | Not provided | Not provided | Not provided | Not provided | Autologous = 4 (2.2%) Nonautologous = 73 (40.3%) Both = 68 (37.6%) |
0 (0%) | Not provided | Not provided | Not provided |
|
| ||||||||||||
| Kim et al. | 44.5 | 7.53 | 21.3 | 2.52 | Not provided | 64 (45.7%) | Not provided | Nonautologous = 140 (100%) | 0 (0%) | Not provided | Not provided | 5 (3.6%) |
|
| ||||||||||||
| Manie et al. | 50 | 41–66 (range)∗ | 36.7 | 31.6–44.9 (range)∗ | Not provided | 5 (35.7%) | Not provided | Not provided | 0 (0%) | 0 (0%) | 1 (7%) | 1 (7%) |
|
| ||||||||||||
| Nahabedian et al. | 48.8 | 35–72 (range)∗ | Not provided | Not provided | Not provided | Not provided | Not provided | Nonautologous = 8 (57.1%) Autologous = 6 (42.8%) |
0 (0%) | 1 (7.1%) | Not provided | 5 (35.7%) |
|
| ||||||||||||
| Ou et al. | 45.2 | 29–67 (range)∗ | 21.8 | 17.48–27.15 (range)∗ | DCIS (12, 27.3%) LCIS (1, 2.3%) IDC (29, 65.9%) ILC (1, 2.3%) Phyllodes (1, 2.3%) |
21 (47.7%) | 7 (15.9%) | Nonautologous = 38 (86.4%) Autologous = 6 (13.6%) |
0 (0%) | 6 (13.6%) | Not provided | 4 (9.1%) |
|
| ||||||||||||
| Pan et al. | 41 (median)∗∗ | 35–45 (IQR)∗∗ | Not provided | Not provided | IDC (27, 65.9%) | 0 (0%) | 45 (100%) | Nonautologous = 41 (100%)∗∗∗ | 0 (0%) | 3 (7.3%) | Not provided | Not provided |
|
| ||||||||||||
| Pek et al. | 47 | 8.8 | 23.5 | 4.5 | Not provided | Not provided | 0 (0%) | Autologous = 148 (84.6%) Nonautologous = 27 (15.4%) |
0 (0%) | 17 (12.0%) | Not provided | 8 (5.6%) |
|
| ||||||||||||
| Peled et al. | 47.8 | 30.4–69.9 (range)∗ | 23.2 | 17.3–27.7 (range)∗ | Not provided | 14 (50%) | 4 (14.3%) | Nonautologous = 46 (100%) | 0 (0%) | 3 (10.7%) | Not provided | 3 (10.7%) |
|
| ||||||||||||
| Peled et al. | Not provided | Not provided | Not provided | Not provided | Not provided | Not provided | Not provided | Nonautologous = 31 (100%) | 31 (100%) | Not provided | Not provided | Not provided |
|
| ||||||||||||
| Petit et al. | 46 | 20–73 (range)∗ | Not provided | Not provided | Invasive carcinoma (819, 82%) IDC (182, 18.2%) |
Not provided | 1001 (100%) | Nonautologous = 991 (99%) Autologous = 10 (1%) |
0 (0%) | 80 (8.0%) | Not provided | 93 (9.3%) |
|
| ||||||||||||
| Rodriguez-Unda et al. | 50.2 | 8.6 | 25.6 | 4.1 | Not provided | 35 (79.5%) | 16 (36.4%) | Nonautologous = 37 (50%) Autologous = 37 (50%) |
0 (0%) | Not provided | Not provided | 108 (245%) |
|
| ||||||||||||
| Shaffer et al. | 48 | 29–63 (range)∗ | Not provided | Not provided | Atypia/DCIS (2, 5%) Invasive cancer (20, 50%) |
12 (30%) | 3, 7.5% | Nonautologous = 74 (100%) | 0 (0%) | 0 (0%) | Not provided | Not provided |
|
| ||||||||||||
| Stanec et al. | 46.6 | 9 | Not provided | Not provided | IDC (212, 50.4%) ILC (71, 16.9%) DCIS (63, 15%) Others (28, 6.5%) |
Not provided | Not provided | Autologous (276, 65.6%) Nonautologous (145, 34.4%) |
0 (0%) | 29 (10.1%) | Not provided | Not provided |
|
| ||||||||||||
| Tevlin et al. | 49 | 10.4 | 28.7 | 4.8 | Not provided | Not provided | 0, 0% | Autologous (14, 100%) | 14 (100%) | Not provided | Not provided | Not provided |
|
| ||||||||||||
| Tomita et al. | 46 | 26–66 (range)∗ | Not provided | Not provided | Not provided | 32 (30.8%) | 70 (67.3%) | Autologous = 104 (100%) | 0 (0%) | Not provided | Not provided | Not provided |
|
| ||||||||||||
| van Verschuer et al. | 40 (median)∗∗ | 26–71 (range)∗ | Not provided | Not provided | Not provided | 5 (11.1%) | 2 (4.4%) | Nonautologous = 45 (100%) | 0 (0%) | 7 (15.6%) | Not provided | 17 (37.8%) |
|
| ||||||||||||
| Wang et al. | 44.22 | 8.56 | Not provided | Not provided | Not provided | 54 (83.3%) | 27 (45.0%) | Autologous = 19 (31.7%) Nonautologous = 37 (61.7%) None = 4 (6.6%) |
0 (0%) | Not provided | Not provided | Not provided |
|
| ||||||||||||
| Yueh et al. | 44 | 25–57 (range)∗ | Not provided | Not provided | Benign breast disease (3, 17.6%) LCIS (2, 11.8%) DCIS (1, 5.9%) Invasive carcinoma (1, 5.9%) |
Not provided | Not provided | Nonautologous = 15 (88.3%) Autologous = 2 (11.7%) |
0 (0%) | 3 (17.6%) | Not provided | 7 (41.1%) |
∗ Data reported as a range. ∗∗Data reported as a median and/or interquartile range (IQR). ∗∗∗Includes delayed reconstruction (22%). All other studies include only immediate reconstruction. DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; IQR, interquartile range; LCIS, lobular carcinoma in situ; NAC, nipple-areola complex; SD, standard deviation.